基因特征指导的药物筛选发现水仙环素可能治疗肾间质纤维化
该研究利用已发表的人类CKD肾脏转录组数据构建肾小管间质纤维化(TIF)特异性基因表达特征,并通过LINCS L1000数据库高通量筛选能逆转TIF相关基因表达的化合物,发现水仙环素可显著逆转TIF基因表达特征,并在多种动物模型中减轻炎症和纤维化病变、延缓已建立的TIF进展,改善5/6肾切除CKD模型的血清肌酐、蛋白尿及TIF和炎症。
要点
- 水仙环素在UUO和缺血再灌注损伤模型中预防炎症和纤维化病变,并延缓已建立的TIF进展。
- 在5/6肾切除CKD模型中,水仙环素降低血清肌酐、减少蛋白尿并缓解TIF和炎症。
- 机制部分通过抑制NF-κB信号通路逆转小管上皮细胞修复失败表型并抑制成纤维细胞增殖活化。
核心结论
- 水仙环素是经基因特征指导筛选出的候选药物,可减轻CKD动物模型的肾间质纤维化和炎症,值得进一步研究。
研究设计与样本
- 利用已发表的人类CKD肾脏转录组数据构建TIF特异性基因表达特征,并使用LINCS L1000小分子扰动库进行高通量筛选。
- 在单侧输尿管梗阻(UUO)、单侧缺血再灌注损伤及5/6肾切除诱导的CKD模型中进行体内验证。
主要发现
- 水仙环素显著逆转TIF的基因表达特征,并在UUO和缺血再灌注损伤模型中预防炎症和纤维化病变。
- 水仙环素延缓UUO诱导的已建立TIF的进展。
- 在5/6肾切除CKD模型中,水仙环素显著降低血清肌酐、减少蛋白尿并缓解TIF和炎症。
- 机制上,水仙环素逆转小管上皮细胞的修复失败表型,抑制成纤维细胞增殖和活化,至少部分通过抑制NF-κB信号通路激活实现。
临床怎么用
- 水仙环素作为潜在抗TIF药物候选,需进一步开展临床前和临床研究验证其疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Chronic Kidney Disease (CKD) is marked by progressive tubulointerstitial fibrosis (TIF), a pathological feature insufficiently addressed by existing therapies. METHODS: To identify drugs with potential to halt TIF progression, we constructed a TIF-specific gene expression signature using published human CKD kidney transcriptome data and employed the small molecule perturbant library LINCS L1000 database for a high-throughput screening of compounds capable of reversing the expression of TIF-related genes. RESULTS: Narciclasine, a natural compound derived from the Narcissus (amaryllis) plant, was identified as a top compound which significantly reversed the gene expression signature of TIF. Administration of narciclasine not only significantly prevented inflammation and fibrotic lesions induced by unilateral ureteral obstruction and unilateral ischemia-reperfusion injury but also delayed the progression of established TIF induced by unilateral ureteral obstruction. Furthermore, in the 5/6 nephrectomy-induced CKD model, narciclasine significantly lowered serum creatinine, reduced proteinuria, and alleviated TIF and inflammation. CONCLUSIONS: Mechanistically, narciclasine reversed the failed-repair phenotype of tubular epithelial cells and inhibited fibroblasts proliferation and activation, at least partially via inhibiting the activation of NF-κB signaling. Our findings suggest that narciclasine should be further investigated as a promising drug candidate to attenuate CKD.
引用
- Xiao A, Chen X, Ma J, et al. Gene signature-guided drug screening identified narciclasine as a potential therapeutic for interstitial fibrosis of the kidney. Kidney Int. 2025. PMID: 40274022. doi:10.1016/j.kint.2025.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。